Axsome's revenue has compounded from $87.2M in Q2 2024 to $259.7M in Q3 2026, with year-over-year growth still at 51.9% and gross margins holding near 93%, which suggests the Auvelity launch is gaining traction.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew to $259.7M in Q3 2026 with a 93.1% gross margin, yet an operating margin of -4.3% and SG&A of $203.1M indicate that operating leverage has emerged but is not yet proven.
Comprehensive stock analysis, price targets, and earnings estimates are available for informed investment decisions.
Detailed stock quotes, historical data, and vital information are accessible for trading and investing strategies.
Real-time stock prices and financial overviews enable investors to monitor performance closely.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | -$0.25+60.6% vs -$0.63 | $260M+4.2% vs $249M |
Q3 2026 Aug 10, 2026 | -$0.99-11.0% vs -$0.89 | $216M-2.2% vs $221M |
Q2 2026 May 4, 2026 | -$1.26-48.2% vs -$0.85 | $189M-0.8% vs $191M |
Q1 2026 Feb 23, 2026 | -$0.71-1.4% vs -$0.70 | $195M+0.7% vs $193M |
Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.
Third-quarter revenue grew 52% year over year to $260 million. Management expects Auvelity to reach $8 billion in peak annual revenue.
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat: Monday, November 9, 2026, at 11:30 a.m. ET in Boston, MA 8th Annual Wolfe Research Healthcare Conference Investor Meetings: Tuesday, November 10, 2026, in New York, NY 2026 Truist BioPharma Symposium Investor Meetings: Thursday, November 12, 2026, in New York, NY UBS Global Biopharma Conference 2026 Fireside Chat: Monday, November 16, 2026, at 11:20 a.m.
Axsome Therapeutics (AXSM) is upgraded to 'Hold' as its valuation now better reflects commercial realities post-ADA approval. AUVELITY's ADA launch is progressing slower than hoped, with incremental growth driven more by under-65 depression scripts than ADA scripts. Q3 results showed a technical beat, but underlying sales were padded by one-time items and improved gross-to-net, not sustainable volume growth.
Benchmark AXSM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Axsome Therapeutics, Inc. (AXSM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $132.37 | $6.81B | -44.14 | 65.55% | -18.18% | -189.73% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $3.86 | $1.7B | 6.18 | 31.26% | 15.79% | 14.95% | 2.56% | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — |
Axsome Therapeutics, Inc. (AXSM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Axsome Therapeutics, Inc. (AXSM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Aug 10, 2026·SEC
Jul 15, 2026·SEC
Get notified when AXSM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Axsome Therapeutics, Inc. (AXSM) stock FAQ — growth, dividends, profitability & financials explained
Axsome Therapeutics, Inc. (AXSM) reported $865.3M in revenue over the trailing twelve months. Revenue was $638.5M in fiscal year 2025.
Axsome Therapeutics, Inc. (AXSM) grew revenue by 54.2% over the trailing twelve months, compared with the twelve months before.
No. Axsome Therapeutics, Inc. (AXSM) reported a net loss of $157.3M over the trailing twelve months.
Axsome Therapeutics, Inc. (AXSM) had a return on equity (ROE) of -189.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Axsome Therapeutics, Inc. (AXSM) had negative free cash flow of $82.0M over the trailing twelve months.
